Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Clinical Inclusion Criteria~* Clinical diagnosis of acute ischemic stroke with unknown symptom onset (e.g., stroke symptoms recognized on awakening)~* Last known well (without neurological symptoms) \> 4.5 hours of treatment initiation~* Measurable disabling neurological deficit (defined as an impairment of one or more of the following: language, motor function, cognition, gaze, vision, neglect)~* Age 18-80 years~* Treatment can be started within 4.5 hours of symptom recognition (e.g., awakening)~* Written informed consent by patient or proxy~Imaging Inclusion Criteria:~* Acute stroke MRI including diffusion weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) completed~* MRI showing a pattern of DWI-FLAIR-mismatch, i.e. acute ischemic lesion visibly on DWI (positive DWI) but no marked parenchymal hyperintensity visible on FLAIR (negative FLAIR) indicative of an acute ischemic lesion ≤4.5 hours of age~Exclusion Criteria:~Clinical Exclusion Criteria~* Planned or anticipated treatment with endovascular reperfusion strategies (e.g. intra-arterial thrombolysis, mechanical recanalization techniques)~* Pre-stroke disability (inability to carry out all daily activities, requiring some help or supervision, i.e. slight disability corresponding to an MRS score \> 1)~* Participation in any investigational study in the previous 30 days~* Severe stroke by clinical assessment (e.g. NIHSS \> 25)~* Hypersensitivity to Alteplase or any of the excipients~* Pregnancy or lactating (formal testing needed in woman of childbearing potential; childbearing potential is assumed in women up to 55 years of age)~* Significant bleeding disorder at present or within past 6 months~* Known haemorrhagic diathesis~* Manifest or recent severe or dangerous bleeding~* Known history of or suspected intracranial haemorrhage~* Suspected subarachnoid haemorrhage (even if CT is negative) or condition after subarachnoid haemorrhage from aneurysm~* History of CNS damage (e.g. neoplasm, aneurysm, intracranial or spinal surgery)~* Recent (within 10 days) traumatic external heart massage, obstetrical delivery, recent puncture of a non-compressible blood-vessel~* Current use of anticoagulants (e.g. Phenprocoumon, Warfarin, new anticoagulants such as Dabigatran) or current use of heparin and elevated thromboplastin time (low-dose subcutaneous heparin is allowed)~* Platelet count \< 100.000/mm3 (\<100G/l)~* Blood glucose \< 50 or \> 400 mg/dl (\< 2.8 or 22.2 mmol/l)~* Severe uncontrolled hypertension, i.e. systolic blood pressure \> 185 mmHg or diastolic blood pressure \>110 mmHg or requiring aggressive medication to maintain blood pressure within these limits (routine medical treatment is allowed to lower the blood pressure below these limits)~* Manifest or recent bacterial endocarditis, pericarditis~* Manifest or recent acute pancreatitis~* Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial aneurysm, arterial/venous malformations~* Neoplasm with increased bleeding risk~* Manifest severe liver disease including hepatic failure, cirrhosis, portal hypertension and active hepatitis~* Major surgery or significant trauma in past 3 months~* Stroke within 30 days~* Life expectancy 6 months or less by judgement of the investigator~* Any condition associated with a significantly increased risk of severe bleeding not mentioned above~* Any contraindication to MRI (e.g. cardiac pacemaker)~Imaging Exclusion Criteria:~* Poor MRI quality precluding interpretation according to the study protocol~* Any sign of intracranial haemorrhage on baseline MRI~* FLAIR showing a marked parenchymal hyperintensity in a region corresponding to the acute DWI lesion indicative of an acute ischemic lesion with a high likelihood of being \> 4.5 hours old~* Large DWI lesion volume \> 1/3 of the MCA or \> 50% of the anterior cerebral artery (ACA) or posterior cerebral artery (PCA) territory (visual inspection) or \> 100 ml~* Any MRI findings indicative of a high risk of symptomatic intracranial haemorrhage related to potential IV-tPA treatment in the judgement of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- intravenous tissue plasminogen activator (Type: EXPERIMENTAL): Intervention drug: intravenous tissue plasminogen activator (tPA), alteplase
- Placebo (Type: PLACEBO_COMPARATOR): Intervention drug: placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).